Houston, Texas


Email Scott Kappes
Scott Kappes
Scott Kappes
Contributor • (866) 529-2400

New Zealand Pulling Avandia Over Cardio Concerns

Comments Off

The New Zealand Ministry of Health has announced that they will be withdrawing the popular diabetes medication Avandia from the market due to cardiovascular concerns.

Rosiglitazone, marketed under the name Avandia, has been under fire for some time following the release of a study that revealed that the drug could be linked to as many as 100,000 heart attacks, strokes, and other heart failures.

Last year the European Union suspended over concerns about the risk of the medication and now authorities in New Zealand have decided to pull the drug from the market.

Medsafe Group Manager Dr. Stewart Jessamine [said] that the recently conducted safety review found that New Zealanders are at a greater risk of suffering from heart diseases on taking the drug.

Patients will be given time to meet with their physicians and explore other treatment options. Avandia will official be pulled on April 29th.